- Home
- SCLX vs FRMM Comparison
SCLX vs FRMM Comparison
Compare SCLX & FRMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCLX | FRMM |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9M | 54.9M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SCLX | FRMM |
|---|---|---|
| Price | $6.82 | $4.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 41.1K | ★ 2.9M |
| Earning Date | 04-10-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $122.52 | $183.55 |
| Revenue Next Year | $186.30 | $166.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.95 | $1.76 |
| 52 Week High | $34.27 | $5.55 |
Technical Indicators
Market Signals| Indicator | SCLX | FRMM |
|---|---|---|
| Relative Strength Index (RSI) | 45.53 | 72.06 |
| Support Level | $6.20 | $2.64 |
| Resistance Level | $7.77 | $5.55 |
| Average True Range (ATR) | 0.72 | 0.55 |
| MACD | 0.10 | 0.31 |
| Stochastic Oscillator | 71.43 | 82.06 |
Price Performance
Historical ComparisonAbout SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.